Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma

NCT00055939 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00055939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Of Intravenous DX-8951f (EXATECAN MESYLATE) Administered Daily For Five Days Every Three Weeks To Pediatric Patients With Relapsed Or Refractory Rhabdomyosarcoma
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2003
Completion date
April 30, 2006
Enrollment
Not reported
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma